Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa

Area of Science:

• Oncology
• Hematology
• Immunology

Background:

• Tumor-associated thrombosis is a major cause of cancer patient mortality.
• Platelet activation is frequently abnormal in cancer patients, necessitating research into underlying mechanisms.
• The role of cancer cell-derived immunoglobulin G (IgG) in platelet activation remains largely unexplored.

Purpose of the Study:

• To investigate the role of cancer cell-derived IgG in platelet activation.
• To elucidate the specific mechanisms by which cancer cell-derived IgG influences platelet function.
• To identify potential therapeutic targets for preventing cancer-associated thrombosis.

Main Methods:

• Flow cytometry to detect platelet activation marker CD62P.
• Platelet aggregation and ATP release assays to assess platelet function.
• Enzyme-linked immune sorbent assay (ELISA) for IgG quantification.
• Immunofluorescence for IgG localization.
• Western blot for FcγRIIa, syk, and PLCγ2 expression.
• Co-immunoprecipitation to analyze IgG-FcγRIIa interaction.

Main Results:

• Cancer patients exhibited elevated CD62P expression on platelets compared to healthy volunteers.
• Cancer cell supernatants enhanced platelet activation (CD62P, PAC-1 expression, aggregation, ATP release).
• Blocking FcγRIIa or reducing IgG levels diminished cancer-induced platelet activation.
• Co-immunoprecipitation confirmed direct interaction between cancer cell-derived IgG and platelet FcγRIIa.
• FcγRIIa was highly expressed in liver cancer patients.

Conclusions:

• Cancer cell-derived IgG directly interacts with platelet FcγRIIa, leading to platelet activation.
• This interaction is a significant contributor to platelet dysfunction in cancer.
• Targeting the cancer cell-derived IgG-FcγRIIa axis presents a promising therapeutic strategy for managing tumor-associated thrombosis.